Novel Sorrento CAR-T technology a potential “game-changer

2 Jan 2018

Company envisions the development and IND filings of multiple “next-frontier” CAR-T programs in 2018 and beyond, which will position the company as a potential major player in the fast-growing CAR-T space of immunotherapies against cancers.

Sorrento Therapeutics' Dr Henry Ji, Chairman & CEO will share recent Sorrento developments and company information in a panel discussion of “R&D Trends: What's Changed in the Pharma Pipeline?” (Saturday, 6 January 3:50 - 4:20 pm PST) in the upcoming “East/West CEO” conference at the Four Seasons Hotel in San Francisco, CA. During the panel discussion, Dr Ji will present the development of a proprietary non-viral chimeric antigen receptor (CAR)-T technology that may fundamentally alter the way that CAR constructs can be integrated into T cells.

Novel Sorrento CAR-T technology a potential “game-changer

This novel Sorrento CAR-T technology has already been utilized preclinically to generate CD38 CAR-T and CD19 CAR-T cells. These CAR-T cells have been evaluated and compared against CAR-T cells generated using current retrovirus transduction methods. Data suggest that the non-virally generated CAR-T cells performed similarly to retrovirally-transduced CAR-T cells with regards to CAR expression, cytokine production, and cytotoxicity against target-expressing tumor cells.

This innovative non-viral CAR-T technology may offer several potential benefits compared with existing virus-based technology using CAR gene-encoding lentivirus, retrovirus or adeno-associated virus (AAV) to introduce CAR constructs into healthy donor (allogeneic) or cancer patient (autologous) T cells. These potential advantages of Sorrento’s non-viral CAR-T technology include

  • site-specific integration of CAR constructs into a pre-selected locus in the T cell genome
  • streamlined method for CAR construct production without need for laborious and time-consuming CAR-encoding virus production, release and validation processes, resulting in a shorter development timeline for IND preparation
  • potential elimination of added burden to patients of lengthy monitoring period for the absence of replication competent virus (i.e., FDA currently requires a 15-year follow-up for patients treated with the virally transduced CAR-T cells)
  • applicability to both autologous and allogeneic CAR-T therapies
  • shortened development timelines to bring new CAR-T therapies faster to patients in need.
  • Sorrento is planning on applying its innovative non-viral CAR-T technology to CAR-T programs for multiple hematological and solid tumor indications, including but not limited to: multiple myeloma, lymphoma, liver cancer, sarcoma, pancreatic cancer and glioma. Utilizing the vast portfolio of target-specific, fully human monoclonal antibodies discovered from its proprietary G-MAB library, Sorrento envisions the development and IND filings of multiple “next-frontier” CAR-T programs in 2018 and beyond, which will position the company as a potential major player in the fast-growing CAR-T space of immunotherapies against cancers.

    “Building on our preclinical and clinical experience in CAR-T cell manufacturing with our “state-of-the-art” cGMP facilities, and looking at the next frontier, we are excited to share this robust development of non-viral CAR-T technology for both autologous and allogeneic CAR-T therapies. This new “game-changer” technology may translate into faster development timelines, more cost-effective cGMP manufacturing and possible removal of the regulatory requirement to follow patients for 15 years post treatment,” stated Dr. Henry Ji. “We also have obtained preclinical data suggesting that cord blood T cells are a potentially rich and valuable “off-the-shelf” T cell source, enabling allogeneic CAR-T therapy. Working with our strategic partner, Celularity, Inc.1, Sorrento intends to develop multiple, potentially paradigm-shifting allogeneic CAR-T programs for hematological and solid tumor indications with high unmet medical need.”

    Read More

    Related news

    SIRIO Pharma opens multimillion gummy production plant

    SIRIO Pharma opens multimillion gummy production plant

    18 Oct 2018

    The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.

    Read more 
    New formulation modelling successes using ex vivo tissue

    New formulation modelling successes using ex vivo tissue

    9 Oct 2018

    One study uses the company's proprietary TurChub model, to evaluate the diffusion and subsequent activity of drugs in human nails.

    Read more 
    Three-way collaboration to advance gene therapy

    Three-way collaboration to advance gene therapy

    4 Oct 2018

    Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

    Read more 
    New oral treatment for metastatic melanoma receives EU authorisation

    New oral treatment for metastatic melanoma receives EU authorisation

    24 Sep 2018

    Encorafenib in combination with binimetinib demonstrated 14.9 months median progression-free survival compared with vemurafenib monotherapy (7.3 months).

    Read more 
    Plasticell wins military contract to develop regenerative medicines for the battlefield

    Plasticell wins military contract to develop regenerative medicines for the battlefield

    4 Sep 2018

    Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

    Read more 
    New biopharmaceutical testing laboratory to open in Geneva

    New biopharmaceutical testing laboratory to open in Geneva

    28 Aug 2018

    SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.

    Read more 
    Exosome isolation manufacturing and characterization

    Exosome isolation manufacturing and characterization

    13 Aug 2018

    New service to reliably and reproducibly isolate exosomes from almost any biofluid.

    Read more 
    Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

    Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

    8 Aug 2018

    Company moves away from manual processing in favour of automated, scalable platforms.

    Read more 
    A new era for migraine patients

    A new era for migraine patients

    6 Aug 2018

    EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

    Read more 
    WuXi STA and Antengene sign development and manufacturing agreement

    WuXi STA and Antengene sign development and manufacturing agreement

    24 Jul 2018

    WuXi STA chosen for its end-to-end CMC platform for new drug development.

    Read more